VYNE — Vyne Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $19.77m
- -$0.15m
- $0.50m
- 37
- 29
- 42
- 28
Annual cashflow statement for Vyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -256 | -73.3 | -23.2 | -28.5 | -39.8 |
| Depreciation | |||||
| Non-Cash Items | 158 | 12.1 | -8.34 | 3.05 | 0.859 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -40.3 | 4.78 | 2.28 | 0.06 | 5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -137 | -56.4 | -29.2 | -25.3 | -34 |
| Capital Expenditures | -0.113 | 0 | — | — | -0.117 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 89.2 | 1.03 | 15.7 | -57.4 | 23.5 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 89.1 | 1.03 | 15.7 | -57.4 | 23.4 |
| Financing Cash Flow Items | -0.141 | -0.294 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 61.8 | 39.8 | 1.65 | 82.4 | -0.141 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.8 | -15.6 | -11.9 | -0.301 | -10.7 |